Initial tests confirm good tolerance

SUCCESS:

Initial tests confirm good tolerance

At three selected epilepsy centres in Germany, the first short-term phase Ib study with outpatients has shown good function and tolerance of the EASEE® stimulation. In 2016/2017, a total of 12 patients each wore the EASEE® platelet electrodes on their scalp on an hourly basis. The innovative system of focused stimulation worked perfectly.
A clinical effect in terms of efficacy could not be determined in the phase Ib study for methodical reasons. Long-term neuromodulation, as the stabilisation of diseased areas of the brain is known, the mode of action on which the EASEE® system is based, does not set in until a few weeks after the platelet electrodes are implanted. After this, there should be a significant reduction in seizures. The long-term study with epilepsy patients starting in 2018 is expected to confirm this.